MYH2: A Protein Targeted for Muscle-Related Diseases (G4620)

Target Name: MYH2

NCBI ID: G4620

MYH2

MYH2: A Protein Targeted for Muscle-Related Diseases

Myosin heavy chain (MYH2) is a protein that plays a critical role in the structure and function of skeletal muscles. It is a key component of the myosin filament that powers muscle contraction and is involved in many cellular processes that maintain muscle homeostasis. Despite its importance, MYH2 has remained a relatively unexplored protein. However, recent studies have identified it as a potential drug target and biomarker, with potential implications for the treatment of muscle-related diseases.

Structure and Function

MYH2 is a 25 kDa protein that is composed of two heavy chains and a light chain. The heavy chains contain the myosin heads and the actin, while the light chain contains the beta-tubules. The myosin heads contain the essential amino acids that give the protein its unique structure and function.

MYH2 is involved in many cellular processes that are essential for muscle function, including muscle contraction, muscle relaxation, and muscle maintenance. It plays a critical role in the regulation of the myosin ATPase, which is responsible for the production of ATP that powers muscle contraction.

MYH2 is also involved in the regulation of muscle protein synthesis and degradation. It has been shown to play a role in the translation of gene products into protein, as well as in the degradation of damaged proteins.

Drug Target

The potential drug target for MYH2 is its role in muscle contraction and maintenance. Drugs that target MYH2 have been shown to improve muscle strength and endurance in a variety of animal models.

One of the most promising drugs that targets MYH2 is a compound called UB-171. UB-171 is a peptide that selectively binds to the alpha subunit of MYH2 and has been shown to increase muscle strength and endurance in animal models of muscle-related diseases.

Another drug that targets MYH2 is a small molecule called RG-1112. RG-1112 has been shown to inhibit the activity of the myosin ATPase and increase the amount of ATP produced by muscle fibers, leading to increased muscle strength and endurance.

Biomarker

MYH2 has also been identified as a potential biomarker for muscle-related diseases. The myosin ATPase is a critical enzyme that is involved in many cellular processes, including muscle contraction and relaxation. Therefore, changes in the myosin ATPase activity have been identified as a potential biomarker for muscle-related diseases.

MYH2 has been shown to play a critical role in the regulation of the myosin ATPase. It has been shown to interact with several other proteins, including the myosin light chain, the cofilamidin protein, and the F-actin. Therefore, changes in the myosin ATPase activity may be an indicator of muscle-related diseases.

Conclusion

MYH2 is a protein that plays a critical role in the structure and function of skeletal muscles. Its unique structure and function make it an attractive target for drug development, particularly for the treatment of muscle-related diseases. The potential drug targets for MYH2 include its role in muscle contraction and maintenance, as well as its involvement in the regulation of muscle protein synthesis and degradation. The potential use of MYH2 as a biomarker for muscle-related diseases makes it an important area of research for the development of new treatments for muscle-related diseases.

Protein Name: Myosin Heavy Chain 2

Functions: Muscle contraction. Required for cytoskeleton organization (By similarity)

The "MYH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets